HAE Acute Treatment from CSL Behring.
Berinert is an intravenous C1 esterase inhibitor for acute treatment of HAE attacks. It is one of the most rapidly effective acute treatments and is appropriate for any attack location — including life-threatening laryngeal involvement.
Berinert is FDA-approved for the following indications:
Berinert is administered intravenously as soon as possible after attack onset. Many patients are trained for self-administration at home, allowing earlier treatment than would be possible if waiting for emergency care.
The manufacturer offers a patient support program — CSL Behring Assurance — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.berinert.com/financial-support.
Treatment with Berinert is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Infusion logistics are coordinated through trusted partner infusion providers — including Horizon Infusions, where the practice is co-located — or arranged for home infusion when appropriate. The team handles scheduling, nursing coordination, and prior-authorization renewals.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.berinert.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Berinert is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.